Načítá se...
Drug Therapy in the Progressed CML Patient with multi-TKI Failure
The aim of this paper is to outline pharmacotherapy of the ‘third-line management of CML’ (progressive disease course after sequential TKI drugs). Current management of CML with multi-TKI failure is reviewed. TKI (bosutinib, ponatinib, dasatinib, nilotinib) and non-TKI (omacetaxine mepussecinate, IF...
Uloženo v:
| Vydáno v: | Mediterr J Hematol Infect Dis |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Università Cattolica del Sacro Cuore
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4344171/ https://ncbi.nlm.nih.gov/pubmed/25745541 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4084/MJHID.2015.014 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|